Streetbeat News

Products Services

XBIT

Xbiotech announces FDA authorization for a Phase II study of Natrunix in rheumatoid arthritis patients. This marks a significant milestone for the company's drug development program.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 1:16 pm

PYPD

PolyPid announced that the FDA has agreed on the design of the SHIELD II Phase 3 trial, which will evaluate D-PLEX₁₀₀ for the prevention of abdominal colorectal surgical site infections.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 1:15 pm

AAPL

Apple is expected to unveil iOS 17 at the Worldwide Developers Conference on June 5, with potential features including app sideloading, Dynamic Island functionality, AR/VR headset integration, a revamped Control Center, and a new Journaling app. The first developer beta is likely to be released in early to mid-June, followed by a public beta in July, and the official release in mid-September.

Portfolio Pulse from Ananya Gairola

May 22, 2023 | 1:12 pm

AAPL

META

Apple is expected to launch a developer version of its mixed-reality headset at the Worldwide Developers Conference in June. Thousands of employees have contributed to the project, which Bloomberg's Mark Gurman calls one of the riskiest launches in decades. Key players involved include Mike Rockwell, Jeff Williams, Dan Riccio, and Greg Joswiak.

Portfolio Pulse from Shanthi Rexaline

May 22, 2023 | 1:07 pm

NRGV

REPT BATTERO has signed a supply agreement with Energy Vault (NYSE:NRGV) to provide 10 GWh of lithium-ion batteries for global BESS deployments. Initial deliveries are expected to start in Q3 2023. The partnership aims to enable successful execution and delivery of short duration and hybrid energy storage solutions to their global customer base.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 1:06 pm

GRI

GRI Bio provided a business outlook and highlighted upcoming milestones for its NKT cell modulators pipeline, focusing on inflammatory, fibrotic, and autoimmune diseases. The company is advancing its lead programs, GRI-0621 and GRI-0803, and expects to reach value-driving milestones in the near term.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 1:04 pm

CELZ

Creative Medical Technology Holdings (NASDAQ: CELZ) announced significant advances in its ImmCelz platform development, which may result in the ability to treat a broader patient population with immune disorders. The company achieved a 75% reduction in donor patient cells, greater purity, and improved functionality while reducing production costs.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:58 pm

INKT

MiNK Therapeutics presented clinical data on its allo-iNKTs (agenT-797) at the American Thoracic Society International Conference, showing a 75% survival rate in patients with severe respiratory distress. The treatment improved lung function, reduced inflammation, and secondary infections.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:57 pm

CHRS

Coherus BioSciences has announced the U.S. launch of its UDENYCA autoinjector, a device designed for the administration of the company's pegfilgrastim biosimilar. The autoinjector aims to improve patient experience and adherence to treatment.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:56 pm

MBOT

Microbot Medical's LIBERTY Surgical Robotic System achieved a 100% success rate in an extended pre-clinical animal study conducted by leading European physicians. The system was found to be intuitive and easy to use, with positive feedback from interventional radiologists. The company plans to enter the human clinical phase in the second half of the year.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:56 pm